title: Cisplatin+Vinorelbine Treatment of Recurrent or Metastatic Salivary Gland Malignancies (RMSGM): A Final Report on 60 Cases.
abstract: Recurrent or metastatic salivary gland malignancies (RMSGM) are not suitable for conventional treatment. We report the clinical outcomes of 60 patients affected by RMSGM who were treated with DDP+VNB as a first-line or second-line scheme.
  
  
  
  Sixty patients between 2001 and 2008, affected by RMSGM were enrolled in this cohort prospective study; they received the following first-line or second-line chemotherapy (CT), for a maximum of 6 cycles: DDP at 80 mg/m on day 1+VNB at 25 mg/m on day 1 and 8, at 3-week intervals.
  
  
  
  Seventy percent of the patients received DDP+VNB as the first-line CT and 30% of them received it as the second-line CT. After 5 cycles (median) of first-line DDP+VNB, 7% of the patients achieved a complete response, 24% achieved a partial response, 33% achieved an no change, and 36% achieved a PD. After 4 cycles (median) of second-line CT, 0 patients achieved a CR, 5% achieved a PR, 33% achieved an NC, and 62% achieved a PD. The median overall survival period was 10 months for those who received the first-line CT and 4 months for those who received the second-line CT. The best ORR (54%) and median survival were observed, during first-line treatment, in adenocarcinomas, whereas undifferentiated tumours were unresponsive with a poor median survival (4.6 mo).
  
  
  
  Adenocarcinomas show the best response and prognosis with DDP+VNB scheme that seems to be an effective and well-tolerated first-line CT for RMSGM, whereas it has only low palliative activity as a second-line CT.
authors.affiliation: *2nd Medical Oncology Division, Città della Salute e della Scienza Hospital of Turin †Surgical Sciences Department, 1st ENT Division, University of Turin ‡ENT Division, Martini Hospital, Turin, Italy.
authors.forename: Mario
authors.initials: M
authors.lastname: Airoldi
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Garzaro
authors.forename: Fulvia
authors.initials: F
authors.lastname: Pedani
authors.forename: Oliviero
authors.initials: O
authors.lastname: Ostellino
authors.forename: Giovanni
authors.initials: G
authors.lastname: Succo
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Riva
authors.forename: Matteo
authors.initials: M
authors.lastname: Sensini
authors.forename: Nertila
authors.initials: N
authors.lastname: Naqe
authors.forename: Elisa
authors.initials: E
authors.lastname: Bellini
authors.forename: Luca
authors.initials: L
authors.lastname: Raimondo
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Pecorari
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell; D002945:Cisplatin / Q000008:administration & dosage*; D005260:Female; D006258:Head and Neck Neoplasms; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D011446:Prospective Studies; D012468:Salivary Gland Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D000077195:Squamous Cell Carcinoma of Head and Neck; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077235:Vinorelbine; D055815:Young Adult
chemical_list: D014747:Vinblastine; D002945:Cisplatin; D000077235:Vinorelbine